Canlyniadau Chwilio - Rick A. Vreman

Getting the Right Evidence After Drug Approval gan Rick A. Vreman, Rick A. Vreman, Hubert G. M. Leufkens, Aaron S. Kesselheim

Connect to this object online.

Real World Data in Health Technology Assessment of Complex Health Technologies gan Milou A. Hogervorst, Milou A. Hogervorst, Johan Pontén, Rick A. Vreman, Rick A. Vreman, Aukje K. Mantel-Teeuwisse, Wim G. Goettsch, Wim G. Goettsch

Connect to this object online.

Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America gan Ivar T. van der Zee, Rick A. Vreman, Lawrence Liberti, Mario Alanis Garza

Connect to this object online.

Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision‐making... gan Rachel R. J. Kalf, Rick A. Vreman, Diana M.J. Delnoij, Marcel L. Bouvy, Wim G. Goettsch

Connect to this object online.

Synergy between health technology assessments and clinical guidelines for multiple sclerosis gan Milou A. Hogervorst, Rick A. Vreman, Anna Zawada, Magdalena Zielińska, Dalia M. Dawoud, Brigit A. deJong, Aukje K. Mantel‐Teeuwisse, Wim G. Goettsch

Connect to this object online.

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs gan Rick A. Vreman, Lourens T. Bloem, Stijn van Oirschot, Jarno Hoekman, Menno E. van der Elst, Hubert GM Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel-Teeuwisse

Connect to this object online.

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies gan Lourens T. Bloem, Rick A. Vreman, Niels W. L. Peeters, Jarno Hoekman, Menno E. van derElst, Hubert G. M. Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel‐Teeuwisse

Connect to this object online.